Clinical trial

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

NCT05659056

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-11-29

PhasePHASE2

Study timeline

Study start (actual)2022-11-29Date precision: day

Registry last updated2024-04-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

Pyrotinib, trastuzumab, paclitaxel-albuminDRUG

Sponsors & collaborators

The First Affiliated Hospital with Nanjing Medical Universitylead sponsor

Jiangsu HengRui Medicine Co., Ltd.collaborator

Mapped research locations

NanjingJiangsu, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05659056 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.